X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds are expected to be allocated mainly to the development of ABX464 (obefazimod), an oral, first-in-class, small molecule, for the treatment of adults with moderately to severely active UC and other potential chronic inflammatory indications.
Lead Product(s): Obefazimod
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kreos Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing August 21, 2023
Details:
ABX464 (Obefazimod), is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory properties.
Lead Product(s): Obefazimod
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
The Company plans to use the net proceeds for the launch and continuation of the clinical programs of ABX464 (obefazimod), the Company's lead drug candidate in clinical development for ulcerative colitis.
Lead Product(s): Obefazimod
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TCGX
Deal Size: $137.7 million Upfront Cash: Undisclosed
Deal Type: Financing February 22, 2023
Details:
ABX464 (Obefazimod), is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory properties.
Lead Product(s): Obefazimod
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
ABX464 (Obefazimod), is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory properties.
Lead Product(s): Obefazimod
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
The ABTECT program aims to confirm obefazimod’s potential to maintain and further improve patient-outcomes over time, as well as its safety and tolerability profile, as already observed during previously conducted Phase 2a and Phase 2b clinical trials in moderate to severe UC.
Lead Product(s): Obefazimod
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
In consultation with international regulators, including both FDA and EMA, obefazimod 25mg and 50mg will be investigated in ABTECT program for treatment of UC in advanced therapies (AT) naive and in AT-failure patients to support future submission of marketing authorizations.
Lead Product(s): Obefazimod
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
ABX464 (obefazimod) is a small molecule that selectively upregulates miR-124 in immune cells. We aimed to assess ABX464 as a treatment for patients with moderate-to-severe, active ulcerative colitis.
Lead Product(s): Obefazimod
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
The planned use of the net proceeds of the Transaction is, based on the Company’s current plans, follows the launch and continuation of the clinical programs of obefazimod (ABX464), the Company’s lead product in advanced development.
Lead Product(s): Obefazimod
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TCGX
Deal Size: $49.2 million Upfront Cash: Undisclosed
Deal Type: Financing September 02, 2022
Details:
ABX464 (obefazimod) is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in Phase 2a and Phase 2b induction trials to treat ulcerative colitis (UC).
Lead Product(s): Obefazimod
Therapeutic Area: Gastroenterology Product Name: ABX464
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
